{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Breast+Cancer&page=25&q=hormone+receptor-positive", "query": { "q": "hormone receptor-positive", "condition": "Breast Cancer", "page": 25 }, "page_size": 10 }, "pagination": { "page": 25, "page_size": 10, "total_count": 678, "total_pages": 68, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Breast+Cancer&page=26&q=hormone+receptor-positive&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Breast+Cancer&page=24&q=hormone+receptor-positive&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-15T20:58:48.744Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00097344", "title": "The CAT Study: Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Neoplasms", "Neoplasms, Hormone-Dependent" ], "interventions": [ { "name": "Atamestane", "type": "DRUG" }, { "name": "Toremifene", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Aromatase inhibition", "type": "DRUG" }, { "name": "Estrogen receptor blocker", "type": "DRUG" }, { "name": "Hormone therapy", "type": "PROCEDURE" }, { "name": "Endocrine therapy", "type": "PROCEDURE" }, { "name": "Antiestrogen therapy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Intarcia Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 842, "start_date": "2004-12", "completion_date": "2006-08", "has_results": false, "last_update_posted_date": "2007-08-23", "last_synced_at": "2026-10-15T20:58:48.744Z", "location_count": 49, "location_summary": "Mobile, Alabama • Tuscon, Arizona • Hot Springs, Arkansas + 46 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Tuscon", "state": "Arizona" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Greenbrae", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00097344" }, { "nct_id": "NCT00601900", "title": "Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Invasive Breast Carcinoma", "Recurrent Breast Carcinoma", "Stage III Breast Cancer AJCC v6", "Stage IV Breast Cancer AJCC v6 and v7" ], "interventions": [ { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Tamoxifen Citrate", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "OTHER", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 394, "start_date": "2008-09-24", "completion_date": "2024-01-29", "has_results": true, "last_update_posted_date": "2026-08-28", "last_synced_at": "2026-10-15T20:58:48.744Z", "location_count": 521, "location_summary": "Mobile, Alabama • Fort Smith, Arkansas • Antioch, California + 355 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Fort Smith", "state": "Arkansas" }, { "city": "Antioch", "state": "California" }, { "city": "Berkeley", "state": "California" }, { "city": "Burbank", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00601900" }, { "nct_id": "NCT03781063", "title": "Evaluation of Lasofoxifene Versus Fulvestrant in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Locally Advanced or Metastatic Breast Cancer" ], "interventions": [ { "name": "Lasofoxifene", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sermonix Pharmaceuticals Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 100, "start_date": "2019-09-20", "completion_date": "2025-05-08", "has_results": false, "last_update_posted_date": "2026-01-28", "last_synced_at": "2026-10-15T20:58:48.744Z", "location_count": 42, "location_summary": "Phoenix, Arizona • Yuma, Arizona • Duarte, California + 36 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Yuma", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03781063" }, { "nct_id": "NCT05169567", "title": "Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Neoplasm", "Neoplasm Metastasis" ], "interventions": [ { "name": "Abemaciclib", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 368, "start_date": "2022-03-11", "completion_date": "2027-12", "has_results": true, "last_update_posted_date": "2026-10-06", "last_synced_at": "2026-10-15T20:58:48.744Z", "location_count": 60, "location_summary": "Phoenix, Arizona • Springdale, Arkansas • Fullerton, California + 52 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "Fullerton", "state": "California" }, { "city": "Los Alamitos", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05169567" }, { "nct_id": "NCT06495164", "title": "A Real-life Study to Understand the Use and Effects of Palbociclib in US Patients With Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Breast Cancer", "Malignant Neoplasm of Breast" ], "interventions": [ { "name": "Palbociclib", "type": "DRUG" }, { "name": "Aromatase inhibitor", "type": "DRUG" }, { "name": "Ribociclib", "type": "DRUG" }, { "name": "Abemaciclib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2024-06-24", "completion_date": "2026-12-30", "has_results": false, "last_update_posted_date": "2025-11-25", "last_synced_at": "2026-10-15T20:58:48.744Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06495164" }, { "nct_id": "NCT02258464", "title": "Study of Radium-223 Dichloride Versus Placebo and Hormonal Treatment as Background Therapy in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Neoplasms" ], "interventions": [ { "name": "Radium-223 dichloride (Xofigo, BAY88-8223)", "type": "DRUG" }, { "name": "Placebo (saline)", "type": "DRUG" }, { "name": "Background hormonal therapy", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 99, "start_date": "2015-03-02", "completion_date": "2019-08-13", "has_results": true, "last_update_posted_date": "2020-08-10", "last_synced_at": "2026-10-15T20:58:48.744Z", "location_count": 11, "location_summary": "Bakersfield, California • La Jolla, California • Aurora, Colorado + 8 more", "locations": [ { "city": "Bakersfield", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Cedar Rapids", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT02258464" }, { "nct_id": "NCT03697200", "title": "Auricular Point Acupressure to Self-Manage Chronic Pain or Aromatase Inhibitor Musculoskeletal Symptoms in Breast Cancer Survivors: Effectiveness and Scientific Underpinnings", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Aromatase Inhibitor", "Musculoskeletal Symptoms", "Postmenopausal Breast Cancer Survivors" ], "interventions": [ { "name": "APA", "type": "OTHER" }, { "name": "Sham APA control", "type": "OTHER" }, { "name": "Education control", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Johns Hopkins University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 102, "start_date": "2018-11-11", "completion_date": "2020-12-30", "has_results": false, "last_update_posted_date": "2021-07-28", "last_synced_at": "2026-10-15T20:58:48.744Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03697200" }, { "nct_id": "NCT07062965", "title": "A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "PF-07248144", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Everolimus", "type": "DRUG" }, { "name": "Exemestane", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 400, "start_date": "2025-08-05", "completion_date": "2030-11-04", "has_results": false, "last_update_posted_date": "2026-05-06", "last_synced_at": "2026-10-15T20:58:48.744Z", "location_count": 102, "location_summary": "Chandler, Arizona • Gilbert, Arizona • Glendale, Arizona + 85 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Goodyear", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT07062965" }, { "nct_id": "NCT02586675", "title": "TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer", "Breast Cancer - Female", "Breast Cancer - Male" ], "interventions": [ { "name": "Tamoxifen", "type": "DRUG" }, { "name": "Ribociclib", "type": "DRUG" }, { "name": "Goserelin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2016-02-23", "completion_date": "2021-10-27", "has_results": true, "last_update_posted_date": "2022-01-21", "last_synced_at": "2026-10-15T20:58:48.744Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02586675" }, { "nct_id": "NCT02999477", "title": "A Study Of Changes In PD-L1 Expression During Preoperative Treatment With Nab-Paclitaxel And Pembrolizumab In Hormone Receptor-Positive Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Nab-Paclitaxel", "type": "DRUG" }, { "name": "Biopsy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Adrienne G. Waks", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2017-02-23", "completion_date": "2026-01-08", "has_results": true, "last_update_posted_date": "2026-01-29", "last_synced_at": "2026-10-15T20:58:48.744Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02999477" } ] }